Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.


Updates from The Motley Fool

Latest updates on Neurocrine Biosciences from Fool.com.
3 Biotech Stocks to Buy in July

Image source: Getty Images. It's been a rough year to be a biotech investor. The market-cap-weigh...

3 Stocks to Get on Your Watchlist

I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. W...

This Week in Biotech

With the  SPDR S&P Biotech Index  up 40% over the trailing-12-month period, it's evident that inv...

This Week's 5 Dumbest Stock Moves

Stupidity is contagious. It gets us all from time to time. Even respectable companies can catch i...



Stock Performance

View Interactive NBIX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Neurocrine Biosciences.
Current Price: $43.23
Prev Close: $43.61
Open: $43.77
Bid: $43.33
Ask: $43.38
Day's Range: $42.75 - $44.34
52wk Range: $31.25 - $57.82
Volume: 584,003
Avg Vol 955,938
Market Cap: $4B
P/E (ttm): -15.20
EPS (ttm): ($2.87)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Neurocrine Biosciences.
CAPS Rating 4 out of 5
 
316 Outperform
46 Underperform
CAPS All Stars
 
83 Outperform
6 Underperform

How do you think Neurocrine Biosciences will perform against the market?



You pick for Neurocrine Biosciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Kevin C. Gorman, CEO

81% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Neurocrine Biosciences.

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers